{"id":40366,"date":"2025-08-29T14:33:33","date_gmt":"2025-08-29T06:33:33","guid":{"rendered":"https:\/\/flcube.com\/?p=40366"},"modified":"2025-08-29T14:33:33","modified_gmt":"2025-08-29T06:33:33","slug":"suzhou-hemacell-receives-nmpa-ind-approval-for-first%e2%80%91in%e2%80%91class-megakaryocyte-injection-thrombocytopenia-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40366","title":{"rendered":"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment"},"content":{"rendered":"\n<p>Suzhou HemaCell Therapeutics, a platelet\u2011regeneration\u2011focused cell\u2011therapy developer, announced that the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) has approved a new drug clinical trial application (IND) for its allogeneic megakaryocyte injection.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-highlights\">Product Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Therapeutic Indication<\/strong><\/td><td>Thrombocytopenia caused by cancer therapy<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>Allogeneic megakaryocyte injection<\/td><\/tr><tr><td><strong>Key Advantages<\/strong><\/td><td>\u2022 Low cost<br>\u2022 High safety profile<br>\u2022 No gene\u2011editing required<br>\u2022 Long\u2011lasting efficacy<br>\u2022 Minimal side\u2011effects<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First IND approval<\/strong> for an allogeneic megakaryocyte product in China.<\/li>\n\n\n\n<li><strong>Second product<\/strong> of HemaCell to receive formal clinical\u2011trial approval; the company\u2019s autologous megakaryocyte injection already secured FDA IND approval.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Positions HemaCell as a pioneer in platelet\u2011regenerative cell therapy.<\/li>\n\n\n\n<li>Expands the global portfolio of cell\u2011based solutions for oncology\u2011related cytopenias.<\/li>\n\n\n\n<li>Provides a scalable, cost\u2011effective alternative to platelet transfusions and recombinant growth\u2011factor therapies.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Initiate Phase\u202fI\/II clinical trials to evaluate safety, tolerability, and platelet\u2011count restoration efficacy in patients undergoing chemotherapy or hematologic malignancy treatment.<\/li>\n\n\n\n<li>Leverage the CDE approval to explore parallel regulatory pathways in the United States and Europe.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Suzhou HemaCell Therapeutics, a platelet\u2011regeneration\u2011focused cell\u2011therapy developer, announced that the Center for Drug Evaluation (CDE)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40367,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,3891],"class_list":["post-40366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-hemacell"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Suzhou\u202fHemaCell Therapeutics (HemaCell) wins approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its allogeneic megakaryocyte injection, the world\u2019s first cell\u2011therapy product to restore platelet counts in cancer\u2011related thrombocytopenia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40366\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Suzhou\u202fHemaCell Therapeutics (HemaCell) wins approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its allogeneic megakaryocyte injection, the world\u2019s first cell\u2011therapy product to restore platelet counts in cancer\u2011related thrombocytopenia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40366\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T06:33:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2906.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment\",\"datePublished\":\"2025-08-29T06:33:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366\"},\"wordCount\":201,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2906.webp\",\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"HemaCell\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40366#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40366\",\"name\":\"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2906.webp\",\"datePublished\":\"2025-08-29T06:33:33+00:00\",\"description\":\"China\u2011based Suzhou\u202fHemaCell Therapeutics (HemaCell) wins approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its allogeneic megakaryocyte injection, the world\u2019s first cell\u2011therapy product to restore platelet counts in cancer\u2011related thrombocytopenia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40366\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2906.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2906.webp\",\"width\":1080,\"height\":608,\"caption\":\"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40366#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Suzhou\u202fHemaCell Therapeutics (HemaCell) wins approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its allogeneic megakaryocyte injection, the world\u2019s first cell\u2011therapy product to restore platelet counts in cancer\u2011related thrombocytopenia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40366","og_locale":"en_US","og_type":"article","og_title":"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment","og_description":"China\u2011based Suzhou\u202fHemaCell Therapeutics (HemaCell) wins approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its allogeneic megakaryocyte injection, the world\u2019s first cell\u2011therapy product to restore platelet counts in cancer\u2011related thrombocytopenia.","og_url":"https:\/\/flcube.com\/?p=40366","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-29T06:33:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2906.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40366#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40366"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment","datePublished":"2025-08-29T06:33:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40366"},"wordCount":201,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40366#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2906.webp","keywords":["Cell-therapy","Clinical trial approval \/ initiation","HemaCell"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40366#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40366","url":"https:\/\/flcube.com\/?p=40366","name":"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40366#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40366#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2906.webp","datePublished":"2025-08-29T06:33:33+00:00","description":"China\u2011based Suzhou\u202fHemaCell Therapeutics (HemaCell) wins approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its allogeneic megakaryocyte injection, the world\u2019s first cell\u2011therapy product to restore platelet counts in cancer\u2011related thrombocytopenia.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40366#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40366"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40366#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2906.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2906.webp","width":1080,"height":608,"caption":"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40366#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou\u202fHemaCell Receives NMPA IND Approval for First\u2011In\u2011Class Megakaryocyte Injection \u2013 Thrombocytopenia Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2906.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40366"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40366\/revisions"}],"predecessor-version":[{"id":40369,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40366\/revisions\/40369"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40367"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}